DTL
CDTX

Dynamic Technology Lab’s Cidara Therapeutics CDTX Stock Holding History

Dynamic Technology Lab’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-562
Closed -$58K – 1045
2018
Q2 		$58K Buy
+562
New +$53.1K 0.01% 921

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Dynamic Technology Lab's CDTX Position: Q3 2018 in Review

Dynamic Technology Lab sold out of Cidara Therapeutics (CDTX) in Q3 2018, closing a stake of 562 shares — an estimated $58K sold.

Dynamic Technology Lab first reported a position in CDTX in Q2 2018 and held it in 1 quarter. The position peaked at $58K in Q2 2018. 59 funds tracked by Wall St. Rank hold CDTX as of Q3 2018.

  • Dynamic Technology Lab reported no remaining Cidara Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Dynamic Technology Lab sold 562 Cidara Therapeutics shares in Q3 2018, an estimated $58K.
  • Dynamic Technology Lab first reported a position in Cidara Therapeutics in Q2 2018 and held it in 1 quarter.
  • Dynamic Technology Lab's Cidara Therapeutics position peaked at $58K in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2018.

Based on Dynamic Technology Lab's 13F filing for Q3 2018, filed 14 Nov 2018.